Literature DB >> 8555468

Targeted gene transfer to human hematopoietic progenitor cell lines through the c-kit receptor.

P Schwarzenberger1, S E Spence, J M Gooya, D Michiel, D T Curiel, F W Ruscetti, J R Keller.   

Abstract

In this report, we describe a novel gene therapy approach for hematopoietic stem/progenitor cells using a specific receptor-mediated gene transfection procedure to target c-kit+ cell lines. The vector consists of plasmid DNA containing a luciferase reporter gene that is condensed by electrostatic forces with polylysine (PL) covalently linked to streptavidin (binds biotinylated ligand) and PL covalently linked to adenovirus (AD; to achieve endosomal lysis) with the final addition of biotinylated steel factor (SLF-biotin). Targeted transfection of growth factor-dependent hematopoietic progenitor cell lines that express c-kit showed specific luciferase gene expression over cell lines that did not express c-kit. This effect was dependent on the dose of SLF-biotin and was competed by excess SLF or with monoclonal antibodies that recognize c-kit and block the binding of SLF to its receptor. Maximum transfection efficiency (> 90%) requires a 2-hour incubation period of the vector with the cells, and maximum gene expression occurred 30 hours later. Removal of the endosomalytic agent, AD, from the vector resulted in the loss of gene expression. Vector targeting was versatile and could be changed by the addition of other biotinylated ligands. In principle, this vector should be broadly applicable to deliver genes to hematopoietic stem/progenitor cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8555468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Efficient c-kit receptor-targeted gene transfer to primary human CD34-selected hematopoietic stem cells.

Authors:  Q Zhong; P Oliver; W Huang; D Good; V La Russa; Z Zhang; J R Cork; R W Veith; C Theodossiou; J K Kolls; P Schwarzenberger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 2.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Receptor-targeted recombinant adenovirus conglomerates: a novel molecular conjugate vector with improved expression characteristics.

Authors:  P Schwarzenberger; J D Hunt; E Robert; C Theodossiou; J K Kolls
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo.

Authors:  S Kim; H Lin; E Barr; L Chu; J M Leiden; M S Parmacek
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

5.  Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens.

Authors:  J S Smith; J R Keller; N C Lohrey; C S McCauslin; M Ortiz; K Cowan; S E Spence
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

6.  Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule.

Authors:  Steven Froelich; Leslie Ziegler; Katie Stroup; Pin Wang
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.